A team of researchers led by JoAnn F. Manson of the Harvard School of Public Health revealed that consumption of walnut oil is significantly correlated to lower risk of type 2 diabetes in women. The disclosure was made in February of this ...
Tags: research, walnut oil, type-2, diabete
More and more consumers and corporations are touting the benefits of "local" foods, often described as "sustainable," "healthy," or "natural." According to the trade publication, Sustainable Food News, "local" as a marketing claim, has ...
Tags: local food, organic food, farming
US-based specialty pharmaceutical firm Par Pharmaceutical has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for clonidine hydrochloride (HCl) extended-release (ER) ...
Tags: Par Pharmaceutical, Medicine
NeuroSigma has received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to begin a Phase III pivotal trial of its Monarch eTNS System. Designed to treat the drug resistant epilepsy, the ...
Tags: Device Trial, NeuroSigma
US regulatory authorities have allowed the marketing of a brain wave test, which can diagnose attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged between six and 17 years. This device, called Neuropsychiatric ...
Specialty pharmaceutical company Tris Pharma's generic pharmaceuticals business has launched Dextroamphetamine Sulfate Oral Solution to treat attention deficit disorder with hyperactivity (ADHD) and narcolepsy in the US. Available through ...
Tags: Tris Pharma, Medicine
Taiwan-based specialty pharmaceutical company TWi Pharmaceuticals has obtained FDA tentative approval for its abbreviated new drug application (ANDA) for Guanfacine Hydrochloride Extended Release tablets 1mg, 2mg, 3mg and 4mg. The central ...
Tags: TWi, FDA, pharmaceutical
Suven Life Sciences, a biopharmaceutical company, has received four product patents for its new chemical entities (NCEs). These patents represent the NCEs for the treatment of disorders associated with neurodegenerative diseases. The ...
The US Food and Drug Administration (FDA) has accepted Neos Therapeutics' new drug application (NDA) 505(b)(2) filing for NT0202, an extended release (XR) orally disintegrating tablet (ODT) formulation of Amphetamine Polistirex. The ...
Pfizer has announced the availability of attention deficit hyperactivity disorder (ADHD) therapy, Quillivant XR (methylphenidate hydrochloride) CII for extended-release oral suspension, in the US. The extended-release liquid ...
Tags: Pfizer, ADHD therapy, Quillivant XR CII
Pfizer is considering buying NextWave Pharmaceuticals, a company that develops a liquid attention deficit hyperactivity disorder drug. In the second quarter of 2012, Pfizer signed an option and merger agreement with NextWave and made a ...
Tags: Pfizer, NextWave Pharmaceuticals, deficit hyperactivity disorder drug
Actavis Group has gained FDA approval to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended-Release Capsules CII (Mixed Amphetamine Salts ER Capsules). The Mixed ...
Tags: FDA, Actavis Group, Amphetamine